<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088084</url>
  </required_header>
  <id_info>
    <org_study_id>PEA2015</org_study_id>
    <nct_id>NCT04088084</nct_id>
  </id_info>
  <brief_title>Effects of Palmitoylethanolamide on Inner Retinal Function in Glaucoma Patients by Pattern Electroretinogram</brief_title>
  <official_title>Effect of Palmitoylethanolamide on Inner Retinal Function in Stable Glaucoma Patients. A Prospective, Randomized, Single Blind, Crossover Clinical Trial by Pattern Electroretinogram.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general purpose of the study is to evaluate the potential beneficial effects of PEA 600
      mg supplementation on RGCs function in subjects with glaucoma by pattern electroretinogram
      after three months of therapy.

      Secondary objectives are to assess effects on intraocular pressure (IOP) values, if any; to
      record visual acuity, visual field, central corneal thickness (CCT), and Optical coherence
      tomography (OCT) (ganglion cell complex - GCC) changes, if any and to follow quality of life
      (QL) perception (general vision -GV and general health - GH of national eye instutute visual
      functioning questionnaire 25 items - NEI VFQ25)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monocentric, randomized, prospective, single blind, two treatment and two period crossover
      study.

      The investigators have proposed a cross-over trial to avoid or to detect the bias due to
      intra-individual variability and because, from preliminary observation, it has been noted
      that the effects of PEA on pattern-electroretinogram (PERG) are completely reversible after
      withdrawal, within one month.

      The investigators didn't considered a placebo treated group because the patient cannot
      interfere with the pattern-electroretinogram PERG measurement that is objective and totally
      patient-independent.

      Study duration 12 months Enrolment period 6 months Minimum Follow-up 6 months Start: January,
      2015; end January, 2016 Total sample size: 40 patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Monocentric, randomized, prospective, single blind, two treatment and two period crossover study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>examiners were blinded to the assumption or not of PEA in addition to topical therapy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To assess effects of PEA 600 mg a tablet a day on pattern electroretinogram PERG examination at three months of therapy.</measure>
    <time_frame>3 months</time_frame>
    <description>changes in amplitude (microVolt) and changes in latency (millisecond) of p50 and n95 waves</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess effects of PEA 600 mg on intraocular pressure (IOP) values</measure>
    <time_frame>3 months</time_frame>
    <description>IOP measure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To record visual field changes</measure>
    <time_frame>3 months</time_frame>
    <description>changes in MD (deciBell-dB) and pattern standard deviation-PSD (deciBell-dB) of visual field parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To follow quality of life - QL - perception using the 25 item National Eye Institute - Visual Functioning Questionnaire (NEI VFQ25)</measure>
    <time_frame>3 months</time_frame>
    <description>changes in the total mean score, in the General vision -GV- and in the general health -GH- subscales scores (scores are presented as a number, higher numbers reflect higher QL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>standard of care+palmitoylethanolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEA was supplemented for 3 months to the standard of care (SOC, topical IOP lowering med)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients were only on topical IOP lowering therapy (SOC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>palmitoylethanolamide (PEA) 600 mg</intervention_name>
    <description>PEA 600 mg was added to topical therapy</description>
    <arm_group_label>standard of care+palmitoylethanolamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  -age 18 years or older

          -  diagnosis of primary open angle glaucoma (POAG)

          -  controlled IOP (&lt;18 mmHg, morning value) with any topical lowering medication
             (beta-blockers, carbonic anhidrase inhibitors, alpha2agonists, prostaglandin analogues
             as monotherapy or as associative therapy; betablocker/carbonic anhydrase inhibitor,
             betablocker/alpha2agonist, prostaglandine/betablocker and alpha2agonist/carbonic
             anhidrase inhibitor fixed combinations as monotherapy or in association);

          -  stable IOP&lt;18 mmHg in the last 2 years

          -  stable disease in the last 2 years (no more than -1 deciBell-dB/year at MD of visual
             field)

          -  at least two reliable visual fields per year in the last 2 years

          -  no filtering surgery or other ocular surgery in the preceding 6 months

          -  written consent to participate to study procedures and data utilization in an
             anonymous form

        Exclusion Criteria:

          -  ocular hypertension with normal optic nerve and visual field

          -  contraindication to PEA

          -  glaucomatous scotomas within 10 degree from fixation

          -  any condition limiting the patient's ability to participate in the study;

          -  other causes of visual field changes, such as cataract, myopic chorioretinopathy,
             macular diseases, retinal vascular occlusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>gemma caterina maria rossi, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>clinica oculistica</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Rossi, Gemma Caterina Maria</investigator_full_name>
    <investigator_title>principal investigator, clinical ophthalmologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palmidrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>data will be published on peer review journal</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>upon publication</ipd_time_frame>
    <ipd_access_criteria>actually not available</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 20, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04088084/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

